Tandem Diabetes Care, Inc. (TNDM)
US — Healthcare Sector
Automate Your Wheel Strategy on TNDM
With Tiblio's Option Bot, you can configure your own wheel strategy including TNDM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TNDM
- Rev/Share 14.885
- Book/Share 1.9654
- PB 8.9141
- Debt/Equity 3.379
- CurrentRatio 2.4429
- ROIC -0.3025
- MktCap 1187897330.0
- FreeCF/Share -1.0573
- PFCF -16.6072
- PE -5.8282
- Debt/Assets 0.5137
- DivYield 0
- ROE -1.1882
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | TNDM | Stifel | -- | Hold | -- | $15 | Oct. 21, 2025 |
| Initiation | TNDM | Oppenheimer | -- | Outperform | -- | $22 | Sept. 8, 2025 |
| Upgrade | TNDM | Citigroup | Sell | Neutral | -- | $10.35 | Aug. 12, 2025 |
| Downgrade | TNDM | Piper Sandler | Overweight | Neutral | -- | $14 | Aug. 7, 2025 |
| Downgrade | TNDM | Citigroup | Neutral | Sell | -- | $14 | July 9, 2025 |
| Initiation | TNDM | Truist | -- | Hold | -- | $24 | June 16, 2025 |
| Initiation | TNDM | Mizuho | -- | Neutral | -- | $20 | April 10, 2025 |
| Downgrade | TNDM | Morgan Stanley | Overweight | Equal Weight | $45 | $22 | March 5, 2025 |
| Downgrade | TNDM | Citigroup | Buy | Neutral | $35 | $24 | March 4, 2025 |
| Downgrade | TNDM | Wells Fargo | Overweight | Equal Weight | $38 | $22 | March 3, 2025 |
News
Tandem Diabetes Care, Inc. (TNDM) Reports Q4 Loss, Lags Revenue Estimates
TNDM
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Negative
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Negative
Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.27 per share a year ago.
Read More
About Tandem Diabetes Care, Inc. (TNDM)
- IPO Date 2013-11-14
- Website https://www.tandemdiabetes.com
- Industry Medical - Devices
- CEO John F. Sheridan
- Employees 2650
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.